CAR-T cell therapy for cancer: current challenges and future directions


Por: Zugasti, I, Espinosa-Aroca, L, Fidyt, K, Mulens-Arias, V, Diaz-Beya, M, Juan, ME, Urbano-Ispizua, A, Esteve, J, Velasco-Hernandez, T and Menendez, P

Publicada: 4 jul 2025 Ahead of Print: 4 jul 2025
Resumen:
Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effective and safe, as AML cells share most surface antigens with healthy hematopoietic stem and progenitor cells (HSPCs). Simultaneously targeting antigen expression on both AML cells and HSPCs may result in life-threatening on-target/off-tumor toxicities such as prolonged myeloablation. In addition, the immunosuppressive nature of the AML tumor microenvironment has a detrimental effect on the immune response. This review begins with a comprehensive overview of CAR-T cell therapy for cancer, covering the structure of CAR-T cells and the history of their clinical application. It then explores the current landscape of CAR-T cell therapy in both hematologic malignancies and solid tumors. Finally, the review delves into the specific challenges of applying CAR-T cell therapy to AML, highlights ongoing global clinical trials, and outlines potential future directions for developing effective CAR-T cell-based treatments for relapsed/refractory AML.

Filiaciones:
Zugasti, I:
 Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Diaz-Beya, M:
 Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Juan, ME:
 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

 Hosp Clin Barcelona, Ctr Diagnost Biomed CDB, Dept Immunol, Barcelona, Spain

 Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Hosp Clin Barcelona, Immunotherapy Joint Platform Hosp Sant Joan Deu, Barcelona, Spain

Urbano-Ispizua, A:
 Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

 Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Esteve, J:
 Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS i, Hematol Dept, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Velasco-Hernandez, T:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

 Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

 Univ Barcelona, Dept Biomed Sci & Med & Hlth Sci, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Institucio Catalana Recerca & Estudis Avancats ICR, Barcelona, Spain

 Inst Recerca Sant Joan Deu SJD, Pediat Canc Ctr Barcelona PCCB, Barcelona, Spain
ISSN: 20959907





Signal Transduction and Targeted Therapy
Editorial
Springer Nature, CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND, China
Tipo de documento: Review
Volumen: 10 Número: 1
Páginas: 210-210
WOS Id: 001522551400001
ID de PubMed: 40610404
imagen Green Submitted, gold

MÉTRICAS